Fujirebio Diagnostics, Inc.
15
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
3 terminated/withdrawn out of 15 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Mesothelioma Early Detection by VOCs
Role: collaborator
Longitudinal Pancreatic Cancer Study
Role: lead
A Prospective Longitudinal Breast Cancer Study
Role: lead
Blood Collection of Patient Presenting in the ED and Prescribed a BNP
Role: lead
Fertility in Healthy Premenopausal Women
Role: lead
A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals
Role: lead
Study Vitamin D in Healthy Individuals
Role: lead
A Prospective Longitudinal Collection of Subjects Diagnosed With Small Cell Lung Cancer
Role: lead
New Biomarkers Evaluating Ovarian Cancer
Role: lead
Blood Collection From Heart Failure Patients to Evaluate for Galectin-3 Measurement Differences Using Various Collection Tubes
Role: lead
The Role of KL-6 in the Clinical Diagnosis of ILD
Role: collaborator
Multiple Biomarkers in Undiagnosed Pleural Effusion
Role: lead
Risk of Ovarian Cancer in Patients With a Pelvic Mass
Role: lead
Ovarian Cancer Risk Estimation in Patients With Pelvic Mass
Role: lead
Survivin Urine mRNA Assay Risk of Bladder Cancer Study
Role: lead
All 15 trials loaded